{"entity":{"id":"drug-target-engagement","kind":"term","name":"Drug target engagement","aka":["cellular target engagement","CETSA","cellular thermal shift assay"],"tldr":"Target engagement asks whether a drug reaches and interacts with its intended target in the tested setting. The effect on the cell and the benefit of treatment need their own measurements.","summary":"The cellular thermal shift assay introduced a way to assess drug-associated changes in protein stability in cells and tissues as evidence of target engagement. The original work examined binding, transport, activation and resistance in defined systems. Engagement evidence must be interpreted within the assay used. It does not by itself demonstrate that the target is required for cancer-cell survival or that the drug's cellular effect is caused by acting on that target.","asOf":"2026-11-11","links":[{"label":"Genetic validation of drug mechanisms (2019)","url":"https://doi.org/10.1126/scitranslmed.aaw8412"},{"label":"Primary cellular thermal shift assay study (2013)","url":"https://doi.org/10.1126/science.1233606"},{"label":"Ball et al., isothermal shift assay in lysates and cells (2020)","url":"https://doi.org/10.1038/s42003-020-0795-6"}],"tags":[],"related":["on-target-drug-validation","experimental-versus-clinical-exposure","functional-variant-evidence"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Target engagement and the evidence ladder. Target engagement asks whether a compound interacts with its intended target in the relevant system. Binding to a purified protein does not show that the compound enters the cell or reaches its target in a tumour, and engagement is also not a change in the target's function, a downstream effect or clinical benefit. Each question needs its own measurement: engagement first, then a measured biological effect, then a check of the causal explanation with controls, then clinical evidence.","Reading a thermal-shift result. The cellular thermal shift assay was introduced to evaluate drug binding to target proteins in cells and tissue samples through ligand-induced thermal stabilisation (Martinez Molina et al. 2013). The readout is the soluble target signal remaining after heating, plotted either against temperature at a fixed compound concentration or against concentration at a fixed temperature, so degrees Celsius and concentration units sit on different axes and the two designs ask different bounded questions. A shift of the compound curve against a matched control supports engagement under those conditions; indirect stability or protein-complex effects can also change the signal, so it is not an inhibition or occupancy percentage, and no universal shift cut-off is given here. The heated aliquots are consumed, so a record should carry the compound, concentration, exposure time, temperature series, cell or tissue system and controls. In an isothermal-shift study with a pan-kinase inhibitor, a large share of non-kinase proteins shifted in cells, which the authors read as in-cell profiling being more likely than lysate profiling to identify indirect binding targets; they recommend lysate profiling to identify targets and in-cell profiling to verify intracellular engagement (Ball et al. 2020).","Probes and medicines. Chemical probes are judged by potency, known selectivity and proven mechanism for the question asked, and the numerical criteria published for them belong to a consortium and target class (Arrowsmith et al. 2015; Workman and Collins 2010); a probe is a research starting point and not evidence of a usable medicine.","Record the named target and its detectability, baseline thermal behaviour, compound exposure, sample system and controls. In a temperature series, temperature changes while concentration is held fixed; in a concentration series, the selected temperature stays fixed. The output is soluble target signal, with different x-axis units in those two designs. Heated aliquots are consumed. An indirect stability change or protein-complex effect can alter the result, and neither a universal shift threshold nor a direct occupancy percentage follows from the plot."],"category":"Methods and models"},"route":"/terms/drug-target-engagement/","neighbours":{"term":[{"id":"antibody-internalization-trafficking","kind":"term","name":"Antibody internalization and intracellular trafficking","route":"/terms/antibody-internalization-trafficking/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"experimental-versus-clinical-exposure","kind":"term","name":"Experimental and clinical drug exposure","route":"/terms/experimental-versus-clinical-exposure/"},{"id":"functional-variant-evidence","kind":"term","name":"Functional evidence for a sequence variant","route":"/terms/functional-variant-evidence/"},{"id":"on-target-drug-validation","kind":"term","name":"On-target validation of drug effects","route":"/terms/on-target-drug-validation/"}]}}